Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...
Live imaging and single-cell sequencing analyses on zebrafish models revealed that noncaloric monosaccharides and glucose similarly induce excessive blood vessel formation due to endothelial cells' ...
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that we have completed enrollment ...
Thymosin Beta-4 (Tβ4) is an endogenously occurring peptide that has drawn significant attention from the scientific community due to its wide-ranging biological properties. Composed of 43 amino acids, ...
The global Age-related Macular Degeneration drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion ...
Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg (generic name: ...
Discover Kodiak Sciences' groundbreaking patent for a dual-action protein construct targeting IL-6 and VEGF, aimed at treating neovascular retinal diseases effectively.
Future Oncol. 2012;8(8):961-987. A National Cancer Institute (NCI)-funded (CA84356), OSU Cancer IRB-approved (2001C0108) and FDA-approved (BB-IND-9803) Phase I clinical trial with a first ...
Medical researchers conducted the largest-ever genome-wide association study of all-cause dementia, finding substantial genetic overlap with vascular dementia. In landmark research, scientists at ...
BARCELONA — Last week, Summit and Akeso set the industry abuzz after their bispecific antibody beat Merck’s Keytruda in a Phase 3 lung cancer trial … ...
Snowflake operates a platform for data analysis by collating disparate sets of data, and it has a growing total addressable market. Salesforce has a cloud-based platform and is a market leader in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback